Phase 2 RCT | Sequencing of Ipilimumab plus Nivolumab and Encorafenib plus Binimetinib for untreated BRAF-mutated metastatic melanoma.

Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)

Commentary: Sequential Treatment With Immunotherapy and Targeted Therapy Denotes OS Benefit in BRAF-Mutant Melanoma – OncLive

Commentary on Twitter

Data from the phase II SECOMBIT trial of treatment sequencing for BRAF-mutant metastatic melanoma suggests that nivo+ipi followed by encorafenib + binimetinib results in better OS than the reverse sequence, although with a greater risk of grade 3-4 AEs: https://t.co/9jC2oMI4Az

— NatureRevClinOncol (@NatRevClinOncol) September 7, 2022